Zacks Investment Research
11 May 2026, 21:46 UTC · 19w ago
Verdict
Source says Buy. We score DVA +1.00 across four claims.
Score confirms the headline.
Buy
Rating stated in the headline
+1.00strongly bullish
What the story claims
4 claims · scored −1 bearish … +1 bullish
Energy prices may remain elevated due to production disruptions in the Middle East, potentially driving investor interest toward defensive healthcare stocks.
More positive than 85% of claims this week
DaVita (DVA) is trading at a 13X forward earnings multiple, offering a discount to its industry average of 17X and the S&P 500's 23X, alongside expectations of 40% EPS growth this year.
So whatA combination of significant expected EPS growth and a discounted forward valuation makes DaVita a compelling value-growth candidate, likely prompting institutional re-evaluation of the stock.
Continue reading
5 related stories
More positive than 98% of ticker scores this week
Scored by the NIS engine · methodology.
Search tags
More positive than 77% of claims this week
Globus Medical (MED) has dipped over 10% in 2026 and trades at a 16X forward earnings multiple, a discount to its industry average of 22X, with EPS expected to spike 17% this year.
So whatA recent double-digit price dip combined with a discounted valuation and strong projected earnings growth strengthens the case for MED as a buy-the-dip opportunity, attracting capital inflows.
More positive than 70% of claims this week
Semiconductors and AI-related stocks continue to lift the broader market.
More positive than 63% of claims this week
Which stocks this story touches
More positive than 98% of ticker scores this week
The company is designated as a top-performing stock with a Zacks Rank #1 (Strong Buy) and strong projected EPS growth.
More positive than 98% of ticker scores this week
Identified as a strong buy-the-dip candidate with a Zacks Rank #1 and appealing valuation.
More positive than 98% of ticker scores this week
The company is mentioned as making a strong argument for investment alongside other Zacks Rank #1 stocks.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
−7.6%
Price is moving against the score
$183.78 vs $198.93 close before publication (May 11) · not market-adjusted
DVA chart →
